COTY enters its Q3 2026 print on May 8 with a striking divergence: short sellers have been cutting positions steadily, while the analyst community remains deeply split on whether the stock is a recovery play or a value trap.
The short-side retreat is the clearest signal in the run-up. Short interest has dropped 18% over the past month, falling to 3.4% of free float — its lowest level in at least six weeks, down from roughly 4.5% in mid-April. The ORTEX short score has also eased, sliding from 54.4 to 48.9 in just over a week. Borrow conditions are relaxed: cost to borrow runs under 0.5%, and availability remains ample. That combination — falling SI, easing short score, cheap borrow — suggests short sellers are not loading up into this print.
Options positioning offers little additional signal. The put/call ratio is running at 0.33, barely a whisker above its 20-day average of 0.33 and well short of the 52-week high of 0.69. Options traders are not paying up for downside protection. The stock itself rebounded 1.6% over the past week but fell 5.7% on Thursday, reclaiming part of a sharp 15.7% one-month rally. That monthly move puts the stock at $2.50 — still well below most analyst targets.
The analyst debate is where the story gets genuinely contested. Citigroup and TD Cowen both raised targets on Thursday ahead of the print — to $2.80 and $2.90 respectively — yet both kept neutral or hold ratings. RBC Capital, on the other hand, reiterates an Outperform with a $8.00 target, a level that implies more than a tripling from the current price. That wide spread reflects a fundamental disagreement: bulls point to Coty's "clean beauty" sustainability positioning and long-term brand equity, while bears flag a promotional-heavy environment squeezing margins, a leadership vacuum following the interim CEO transition, and limited exposure to high-growth areas like skincare and China. Barclays remains outright negative at Underweight with a $2.00 target. Net debt is heavy at $4 billion against an enterprise value of roughly $6.6 billion, and revenue fell 5.6% year-over-year in the most recent quarter. On the bright side, EPS momentum over the past 30 days ranks in the 81st percentile, and EPS surprise ranks at the 100th — the company has been beating estimates. The RSI14 of 70.6 flags the stock as technically overbought after its recent run.
The earnings release will test whether Coty's guidance and margin trajectory can justify either the recovery optimism baked into the recent rally or the structural skepticism that still surrounds the business.
See the live data behind this article on ORTEX.
Open COTY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
